Argentum responds to recent decision in patent lawsuit against Noble Biomaterials

Mar 15 2011

Argentum Medical, LLC today issued a response to the recent decision in their patent infringement litigation versus Noble Biomaterials, Inc.

"The most important thing to know is the trial has no impact on our patents and it is business as usual for Argentum," said Gregg Silver, Chairman and CEO of Argentum Medical, LLC. "The case concerned non-patent issues and is currently being appealed. We are confident that our appeal will be successful."

Argentum Medical is an industry leader in antimicrobial silver dressings. The company manufactures more than 60 different combinations and sizes of Silverlon® products, and has developed 14 unique categories of wound, burn and post-surgical dressings. Argentum has sold more than three million dressings to more than 2,000 customers, including the Mayo Clinic, Johns Hopkins University, University of Michigan and the Department of Defense.

This month marks Argentum Medical's 10th anniversary. The company has experienced record sales in 2010, with the Silverlon Surgical Wound Pad and Island Dressings achieving domestic sales growth of more than 300% in the second half of the year.

Silver adds, "The litigation will not affect our customers. We will continue to provide our customers with Silverlon® and our other leading products. We are a financially strong company, and service to our customers will not be affected by any expenses resulting from this lawsuit."

Argentum prides itself on groundbreaking innovation, and has particular success with its Silverlon® Negative Pressure Dressing (NPD), which was named Innovative Product of the Year by Frost and Sullivan in 2006. NPD continues to be one of the company's fastest growing categories today. It was the first antimicrobial silver dressing designed to be utilized with negative pressure wound therapy.